393 related articles for article (PubMed ID: 19562641)
1. Recent progress in the discovery and development of negative allosteric modulators of mGluR5.
Lindsley CW; Emmitte KA
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):446-57. PubMed ID: 19562641
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in the development of allosteric modulators of mGluR5.
Rodriguez AL; Williams R
Curr Opin Drug Discov Devel; 2007 Nov; 10(6):715-22. PubMed ID: 17987523
[TBL] [Abstract][Full Text] [Related]
3. Efficacy switching SAR of mGluR5 allosteric modulators: highly potent positive and negative modulators from one chemotype.
Sams AG; Mikkelsen GK; Brodbeck RM; Pu X; Ritzén A
Bioorg Med Chem Lett; 2011 Jun; 21(11):3407-10. PubMed ID: 21531137
[TBL] [Abstract][Full Text] [Related]
4. Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate receptor 1.
Noeske T; Trifanova D; Kauss V; Renner S; Parsons CG; Schneider G; Weil T
Bioorg Med Chem; 2009 Aug; 17(15):5708-15. PubMed ID: 19574055
[TBL] [Abstract][Full Text] [Related]
5. Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators.
Chae E; Shin YJ; Ryu EJ; Ji MK; Ryune Cho N; Lee KH; Jeong HJ; Kim SJ; Choi Y; Seok Oh K; Park CE; Soo Yoon Y
Bioorg Med Chem Lett; 2013 Apr; 23(7):2134-9. PubMed ID: 23434029
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the vasopressin system for the treatment of CNS diseases.
Ryckmans T
Curr Opin Drug Discov Devel; 2010 Sep; 13(5):538-47. PubMed ID: 20812145
[TBL] [Abstract][Full Text] [Related]
7. Hit-to-lead optimization of disubstituted oxadiazoles and tetrazoles as mGluR5 NAMs.
Wágner G; Wéber C; Nyéki O; Nógrádi K; Bielik A; Molnár L; Bobok A; Horváth A; Kiss B; Kolok S; Nagy J; Kurkó D; Gál K; Greiner I; Szombathelyi Z; Keseru GM; Domány G
Bioorg Med Chem Lett; 2010 Jun; 20(12):3737-41. PubMed ID: 20483612
[TBL] [Abstract][Full Text] [Related]
8. Novel heterocyclic compounds as mGlu5 antagonists: WO2009015897.
Doller D; Li G; Brodbeck RM; Thomsen C
Expert Opin Ther Pat; 2010 Mar; 20(3):435-9. PubMed ID: 20180623
[TBL] [Abstract][Full Text] [Related]
9. Allosteric modulators of metabotropic glutamate receptors: lessons learnt from mGlu1, mGlu2 and mGlu5 potentiators and antagonists.
Johnson MP; Nisenbaum ES; Large TH; Emkey R; Baez M; Kingston AE
Biochem Soc Trans; 2004 Nov; 32(Pt 5):881-7. PubMed ID: 15494040
[TBL] [Abstract][Full Text] [Related]
10. Fragment-based ligand discovery.
Fischer M; Hubbard RE
Mol Interv; 2009 Feb; 9(1):22-30. PubMed ID: 19299661
[TBL] [Abstract][Full Text] [Related]
11. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5.
O'Brien JA; Lemaire W; Chen TB; Chang RS; Jacobson MA; Ha SN; Lindsley CW; Schaffhauser HJ; Sur C; Pettibone DJ; Conn PJ; Williams DL
Mol Pharmacol; 2003 Sep; 64(3):731-40. PubMed ID: 12920211
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of metabotropic glutamate receptor allosteric modulators: structural basis and therapeutic potential for CNS disorders.
Gregory KJ; Noetzel MJ; Niswender CM
Prog Mol Biol Transl Sci; 2013; 115():61-121. PubMed ID: 23415092
[TBL] [Abstract][Full Text] [Related]
13. Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential.
Kew JN
Pharmacol Ther; 2004 Dec; 104(3):233-44. PubMed ID: 15556676
[TBL] [Abstract][Full Text] [Related]
14. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors.
Chen Y; Goudet C; Pin JP; Conn PJ
Mol Pharmacol; 2008 Mar; 73(3):909-18. PubMed ID: 18056795
[TBL] [Abstract][Full Text] [Related]
15. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo.
Lindsley CW; Wisnoski DD; Leister WH; O'brien JA; Lemaire W; Williams DL; Burno M; Sur C; Kinney GG; Pettibone DJ; Tiller PR; Smith S; Duggan ME; Hartman GD; Conn PJ; Huff JR
J Med Chem; 2004 Nov; 47(24):5825-8. PubMed ID: 15537338
[TBL] [Abstract][Full Text] [Related]
16. Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA.
Zhao Z; Wisnoski DD; O'Brien JA; Lemaire W; Williams DL; Jacobson MA; Wittman M; Ha SN; Schaffhauser H; Sur C; Pettibone DJ; Duggan ME; Conn PJ; Hartman GD; Lindsley CW
Bioorg Med Chem Lett; 2007 Mar; 17(5):1386-91. PubMed ID: 17210250
[TBL] [Abstract][Full Text] [Related]
17. Negative allosteric modulators of group II metabotropic glutamate receptors: A patent review (2015 - present).
Qunies AM; Emmitte KA
Expert Opin Ther Pat; 2021 Aug; 31(8):687-708. PubMed ID: 33719801
[TBL] [Abstract][Full Text] [Related]
18. Discovery, synthesis, and structure-activity relationships of 2-aminoquinazoline derivatives as a novel class of metabotropic glutamate receptor 5 negative allosteric modulators.
Kubas H; Meyer U; Krueger B; Hechenberger M; Vanejevs M; Zemribo R; Kauss V; Ambartsumova R; Pyatkin I; Polosukhin AI; Abel U
Bioorg Med Chem Lett; 2013 Aug; 23(16):4493-500. PubMed ID: 23856046
[TBL] [Abstract][Full Text] [Related]
19. Antagonists at metabotropic glutamate receptor subtype 5: structure activity relationships and therapeutic potential for addiction.
Carroll FI
Ann N Y Acad Sci; 2008 Oct; 1141():221-32. PubMed ID: 18991960
[TBL] [Abstract][Full Text] [Related]
20. New developments in the discovery of small molecule Hedgehog pathway antagonists.
Tremblay MR; McGovern K; Read MA; Castro AC
Curr Opin Chem Biol; 2010 Jun; 14(3):428-35. PubMed ID: 20399136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
